INDIA, A DESTINATION OF CHOICE FOR CLINICAL TRIALS:
HOW DO WE GAIN LOST GROUND

Chair & Speaker:

Dr. Shoibal Mukherjee
Chief Medical Officer
Quintiles India & Head, Asia Medical Sciences Group
Quintiles Research Pvt. Ltd.
Regus Business centre,
Unit No. 1234 & 1238, Level 12,
Building No 8C, DLF Cyber city,
Gurgaon – 122002, Haryana
Email: Shoibal.Mukherjee@quintiles.com

Profile:

Dr Shoibal Mukherjee is Chief Medical Officer, Quintiles India and Head, Quintiles Asia Medical Sciences Group. In his role as Chief Medical Officer, Dr Mukherjee is responsible for the high-level oversight of ethics, quality and safety in clinical operations. He provides stewardship and leads advocacy for the highest standards of clinical research in the country, driving internal and externally directed initiatives to achieve this goal. He also mentors the Asia Medical Sciences group, a team of medics located across Asia-Australia that provides medical and technical support to clinical projects in the region as part of the Drug Development team in Asia.

Dr Mukherjee joined Quintiles in May, 2011, and brings with him over 20 years of rich experience in medical affairs, clinical research, clinical data management, medical and regulatory writing, global pharmacovigilance and quality. Prior to joining Quintiles, he was with GVK Biosciences where he was a member of the Executive Committee and Senior Vice President & Head of the Clinical Development strategic business unit. He has also held leadership positions as Medical Director of Pfizer India and Vice President, Medical Affairs and Clinical Research of Ranbaxy Laboratories.

Dr Mukherjee is a postgraduate in Medicine and Clinical Pharmacology, and has a Masters in Pharmaceutical Medicine from Hibernia College, Ireland. He was the Founder President of the Indian Society for Clinical Research and has been closely involved with the evolution of pharmaceutical regulation in the country. He is a member of the Clinical Trials Task Force of the FICCI and served as a member of the Schedule Y Review Committee whose recommendations led to the revision of clinical trial and new product submission
requirements in early 2005. Dr Mukherjee has numerous publications to his credit and is an active speaker at industry seminars and conferences, besides being a guest faculty at several leading medical and pharmacy institutions in the country.

*******************************

Speakers:

Dr. Abhijit Barve
President R&D
Biocon Research Limited
Biocon Special Economic Zone,
Plot No.2&3, Phase IV- B.I.A,
Bommasandra-Jigani Link Road,
Bangalore - 560 099, India
Email: abhijit.barve@biocon.com

Title:
India as Global Destination for Trials: How did we lose the plot

Abstract:
How the explosive growth with limited check and balances, high turnover of trained manpower along with hype created by consulting firms on the size of market impacted public perception and how some of the lapses were blown out of proportion by media and NGO leading to the current state of affairs.....

Profile:

Dr. Abhijit Barve is the President, R&D of Biocon Research Centre since November 2011. He was the Chief Operating Officer of Clinigene International Limited, a Biocon subsidiary considered to be amongst India’s premier Clinical Research Organizations (CRO). Prior to joining Clinigene he was with Astellas Pharma Inc in Deerfield, IL, USA. Abhijit has over 15 years of global drug development experience covering preclinical, early and late stage clinical development, clinical operations, regulatory and safety functions. During this timeframe, he has filed at least a dozen IND applications and has extensively interacted with various divisions of the FDA and also with EMEA and PMDA. Abhijit joined Fujisawa Research Institute of America as Asst. Medical Director in 1999. His last role prior to joining Clinigene in April 2010, was Global Development Project Leader for CNS programs. Abhijit trained at LTM Medical College and Seth G.S Medical College & KEM Hospital, Mumbai where he received his MBBS and MD degrees in 1992 and 1995, respectively. He subsequently received his PhD from Dept. of Biopharmaceutical Sciences, University of
Illinois at Chicago in 1999. In 2007, he received his MBA in Finance, Entrepreneurship and Strategy with Honors from the University of Chicago, Booth School of Business.

**Speakers:**

**Dr. Arun Bhatt**  
President,  
Clininvent Research Pvt. Ltd.  
A-103, Everest Chambers  
Marol Naka, Andheri - Kurla Road  
Andheri (E)  
Mumbai - 400 059, India  
Phone: + 91-22-6781 8600  
Fax: + 91-22-6781 8701  
E-mail: arunbhatt@clininvent.com

**Title:**

Clinical Research in India: Paradigm Shift from Cost to Compliance!

**Abstract:**

Since Jan 2013, the Indian regulatory authorities have announced a spate of laws and guidelines, which will have a huge impact on the clinical trial sector in India. The approval process is more challenging and longer; the recruitment of patients is likely to be slower and the cost is likely to increase because of compensation rules, increase in site / EC requirements, and additional monitoring / audits to ensure inspection readiness and regulatory compliance. The new stringent and tough regulatory milieu requires a paradigm shift from quantity to quality, and cost to compliance!

**Profile:**
Dr Arun D Bhatt is the President, Clinivent Research Private Limited.

Dr Bhatt has extensive experience of over three decades in the Indian pharmaceutical industry. He has worked as a consultant in pharmaceutical medicine and clinical pharmacology. His past positions held include CEO of CMI (India) Private Limited and Medical Director of Novartis India Limited.

Dr Bhatt has been active in industry associations and was earlier the President of Indian Society for Clinical Research (ISCR). He is joint Editor-in-Chief of Perspectives in Clinical Research – the journal of ISCR.

In 2009, the Institute of Clinical Research UK nominated Dr Bhatt for the Honorary Fellowship of Institute of Clinical Research.

Dr Bhatt is recipient of Drug Information Association outstanding Service award 2012 for his immense contributions in his field of specialization.

Dr Bhatt delivered the prestigious Prof U K Sheth Oration in 2013.

Dr Bhatt is the Founder of Training Resource Academy and Information Nucleus (www.traain.com), a unique web resource for clinical research professionals, investigator sites, and ethics committees.

Dr Bhatt has more than 100 publications in national and international journals. He runs a regular monthly column on “Good Clinical Practice – Question Answers” and has published a book “Clinical Trials and Good Clinical Practice in India – Your Questions Answered”.

*********************

**Speakers**

**Mr. Anil Panwar**

Chief Executive Officer

Fortis Clinical Research Ltd. (FCRL)

Sunflag Hospital & Research Centre

Sector-16A, Faridabad - 121 002, India

Email: anil.panwar@fortis-cro.com

**Profile:**
Mr. Anil Panwar, a fellow member of the Institute of Chartered Accountants of India, started his professional career in the Industry with DCM Ltd. way back in 1976 and later on moved to Britannia Industries. Thereafter, he had a long stint of about 20 years in Escorts Group at various positions and was involved in almost every facet in finance – right from operational finance to corporate finance, treasury, strategy, financial planning and so on. He has to his credit several joint venture and divestment deals that clearly reflected his sound business acumen, astute foresight and the ability to think beyond the obvious. Besides, doing the restructuring of Escorts Group, he successfully managed the public issue and right issues of Escorts Group.

Mr. Panwar joined Fortis Group in year 2002 as Director-Group Finance. In his tenure at Fortis, he has taken the Group to new heights of growth, financial achievement and recognition through his creativity, passion, innovative approach and leadership skills and has come to known as restructuring and M&A specialist. He concluded the biggest M&A deal in the Healthcare delivery in India, i.e., Escorts Hospital Group which has made Fortis the largest player in the Healthcare delivery in North India and second largest player in pan India, besides making the Fortis- Escorts combination the world's largest Cardiac care facility. As a senior member of the management team, Mr. Panwar has stepped far beyond a role of traditional finance person to help Fortis design a long term strategic growth plan. He has played a very crucial role in setting a tone of trust, integrity, and commitment to ethical business conduct within the culture of the Group. As an ethical watchdog within the Group, he has been responsible for creating concrete measures to maintain and protect a transparent, well-balanced system of corporate governance that goes beyond just compliance.

Mr. Panwar left Fortis in June 2008 and joined IVEN Medicare Pvt. Ltd. as a Chief Executive Officer where he was responsible for Profit centre responsibility, Joint Venture Negotiations, Management of JV partners, Funds raising, Review of JV’s, Identification & negotiation with potential JV partners-Strategy & Planning.
In November, 2008 he joined back Fortis Group as a Chief Strategy Officer in RHC Holding Private Limited (holding company of Fortis Healthcare India operations) where he is responsible for looking after group holding Cos, Taxation and he is holding the additional responsibility of CEO of a Fortis Clinical Research Ltd.